Stock listing

KRX:372320 Curocell, Inc. (큐로셀) 주가

Follow Curocell, Inc. into a list and get an email when it puts out news.

Share price · KRX:372320

₩21,200 KRW +50 (+0.2%)

Close on Nov 20, 2026

Past year -49.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩20,950 – ₩21,500 KRWNov 20, 2026
Volume
12,306 sharesNov 20, 2026
Market cap
₩322.8B KRWAt the close on Nov 20, 2026 · price × 15.23M shares outstanding
52-week range
₩20,300 – ₩66,000 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩673.0M KRWMedian day 21,372 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Curocell, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:372320 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩21,200+50+0.2%₩21,500₩21,500₩20,95012,306
₩21,150-250-1.2%₩21,400₩22,050₩20,90015,845
₩21,400-100-0.5%₩21,400₩22,000₩20,95023,329
₩21,500-800-3.6%₩22,150₩22,900₩21,20023,021
₩22,300-450-2.0%₩22,700₩23,450₩22,20015,938
₩22,750-750-3.2%₩22,850₩23,550₩22,40010,703
₩23,500+1,250+5.6%₩21,950₩23,600₩21,95024,848
₩22,250+900+4.2%₩21,550₩22,500₩21,55013,324
₩21,350+300+1.4%₩21,000₩22,300₩20,30037,384
₩21,050-2,250-9.7%₩21,500₩22,800₩20,800103,416
₩23,300+950+4.3%₩23,550₩24,250₩22,75035,454
₩22,350-150-0.7%₩22,750₩23,250₩21,40027,039
₩22,500-600-2.6%₩23,400₩23,400₩22,45022,906
₩23,100+50+0.2%₩22,400₩23,550₩22,40021,604
₩23,050-650-2.7%₩23,000₩23,450₩22,50020,734
₩23,700-1,300-5.2%₩25,000₩25,000₩23,55031,735
₩25,000+600+2.5%₩24,900₩26,850₩24,75040,616
₩24,400+1,100+4.7%₩23,250₩24,900₩23,10027,005
₩23,300+150+0.6%₩23,300₩23,300₩22,20019,146
₩23,150-250-1.1%₩22,850₩23,200₩22,30021,460
₩23,400-450-1.9%₩23,950₩23,950₩23,25018,268
₩23,850-200-0.8%₩24,150₩24,600₩23,75016,130
₩24,050+50+0.2%₩24,500₩24,750₩23,35029,508
₩24,000+500+2.1%₩22,000₩24,300₩22,00016,187
₩23,500+1,850+8.5%₩21,800₩23,850₩21,50031,791
₩21,650-1,100-4.8%₩22,200₩22,350₩21,25044,040
₩22,750-400-1.7%₩23,400₩23,450₩22,45026,750
₩23,150-850-3.5%₩23,150₩23,400₩22,30039,507
₩24,000-2,150-8.2%₩26,000₩26,000₩23,90061,662
₩26,150-350-1.3%₩25,500₩26,800₩24,15072,080
₩26,500+3,800+16.7%₩24,000₩26,750₩23,350206,383
₩22,700-300-1.3%₩23,000₩23,550₩22,60026,413
₩23,000+150+0.7%₩23,000₩23,450₩22,60031,345
₩22,850+1,200+5.5%₩21,800₩23,000₩21,55043,361
₩21,65000.0%₩22,000₩22,150₩21,40011,252
₩21,650+50+0.2%₩21,600₩22,200₩20,85015,695
₩21,600+400+1.9%₩21,800₩22,500₩21,35041,818
₩21,200+300+1.4%₩21,250₩21,300₩20,80013,937
₩20,900-150-0.7%₩21,100₩21,350₩20,85017,546
₩21,050-400-1.9%₩21,450₩21,700₩21,00011,160
₩21,450-50-0.2%₩21,800₩21,800₩21,15017,156
₩21,500+50+0.2%₩21,550₩21,750₩20,85012,971
₩21,450-600-2.7%₩22,300₩22,350₩21,25016,700
₩22,050+50+0.2%₩22,050₩22,450₩21,65015,565
₩22,000-850-3.7%₩22,350₩22,650₩21,65033,757
₩22,850+50+0.2%₩22,800₩23,100₩22,45015,986
₩22,800-1,200-5.0%₩23,750₩23,750₩22,80042,286
₩24,000+300+1.3%₩23,600₩24,000₩23,40014,684
₩23,700-300-1.3%₩24,350₩24,350₩23,70021,671
₩24,000-50-0.2%₩24,300₩24,300₩23,75012,788
₩24,05000.0%₩26,100₩26,100₩23,75049,132
₩24,050-50-0.2%₩24,600₩24,600₩23,50017,242
₩24,100+150+0.6%₩23,600₩24,150₩23,20013,359
₩23,950-450-1.8%₩24,400₩24,450₩23,55017,033
₩24,400-250-1.0%₩24,500₩24,550₩23,40017,231
₩24,650-350-1.4%₩24,850₩25,300₩24,40010,623
₩25,000-150-0.6%₩25,250₩25,550₩24,90018,552
₩25,150+1,050+4.4%₩24,450₩25,350₩24,15025,372
₩24,100+300+1.3%₩23,500₩24,100₩22,75019,912
₩23,800+400+1.7%₩24,350₩24,350₩23,25021,284
₩23,400-1,700-6.8%₩24,350₩24,700₩23,25024,929
₩25,100+400+1.6%₩26,200₩26,200₩24,80018,122
Ticker
KRX:372320
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
KRX
Currency
KRW

Latest news

All Curocell, Inc. news

Curocell, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in all · newest Oct 13, 2025 · oldest 2025

Valuation

Price/book 4.5× against a median of 1.8×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩257.6B KRW
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.2×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Curocell, Inc. · KRX:372320US$241.3MUS$192.5Mn/an/an/a4.5×n/a0.2×n/a
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Q32 Bio Inc. · NASDAQ:QTTBUS$249.6M−US$35.66M7.7×−0.7×−1.9×0.9×59.8%0.0×0.59
Turn Therapeutics Inc. · NASDAQ:TTRXUS$247.5MUS$244.2Mn/an/an/a43.5×n/a1.1×1.54
Mabpharm Limited · HKEX:2181US$247.3MUS$279.4M29.7×3.0×28.9×8.5×8.8%1.6×n/a
Lexeo Therapeutics, Inc. · NASDAQ:LXEOUS$245.1MUS$56.52Mn/an/an/a1.1×n/a0.0×1.62
Shandong Boan Biotechnology Company., Limited. Class H · HKEX:6955US$242.7MUS$93.26M227×0.8×4.7×0.6×0.9%0.0×n/a
Clinuvel Pharmaceuticals Limited · ASX:CUVUS$238.9MUS$73.38M10.3×1.1×2.6×1.3×36.0%0.0×n/a
CAMP4 Therapeutics Corporation · NASDAQ:CAMPUS$237.8MUS$119.8Mn/a22.5×n/a2.2×n/a0.1×1.70
Valerio Therapeutics · EURONEXT:ALVIOUS$228.9MUS$242.3Mn/a85.8×50.8×n/a−190.4%n/an/a
Scribe Therapeutics Inc. · NASDAQ:SCTXUS$228.5MUS$59.42Mn/a1.2×n/a1.8×−42.6%0.0×n/a
Median of the othersUS$243.9MUS$106.5M20.0×1.8×4.7×1.8×0.9%0.0×1.62

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue000
Cost of revenue000
Gross profit000
Research and development31.3B31.9B27.2B19.7B13.2B
Selling, general and administrative1.04B4.66B3.85B1.72B464.0M
Operating income-36.3B-36.6B-31.1B-21.4B-15.3B
Depreciation and amortization6.12B6.32B4.70B1.82B1.71B
EBITDA-30.2B-30.3B-26.4B-19.6B-13.6B
Interest expense4.54B2.60B2.43B207.3M195.2M
Income before tax-46.3B-38.2B-29.7B-38.9B-53.6B
Net income-46.3B-38.2B-29.6B-38.9B-53.6B
Earnings per share, basic-3,073.95-2,693.04-2,172.59-2,856.52-3,935.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents10.2B4.58B9.92B6.63B42.6B
Short-term investments14.0B5.00B30.0B500.0M19.8B
Receivables3.32M91.3M372.8M
Inventory1.68B
Current assets32.3B13.0B42.8B41.4B64.2B
Property, plant and equipment55.4B61.2B46.1B
Total assets109.7B72.0B105.0B88.0B82.2B
Current liabilities97.0B38.8B3.27B106.6B84.8B
Long-term debt039.6B26.1B6.61B
Total liabilities104.7B42.6B45.9B135.6B94.4B
Shareholders' equity5.03B29.5B59.1B-47.6B-12.2B
Shares outstanding15.1M14.2M13.6M13.6M13.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-30.0B-28.4B-25.3B-14.4B-11.5B
Capital spending-2.22B-1.21B-21.7B-27.9B-9.30B
Free cash flow-32.2B-29.6B-46.9B-42.3B-20.8B
Cash from investing22.0B-21.1B-40.7B
Cash from financing1.04B49.7B19.1B
Share buybacks1.56B32.2B54.1M
Change in cash5.58B-5.34B3.29B-36.0B39.2B

Open Financials

Cap table

Built by 6ix from Curocell, Inc.’s releases

Common shares
15,225,918
Fully diluted
15,225,918

Fully diluted

LineShares
Common shares15,225,918

Share count over time

CountShares
Nov 22, 202615,225,918

Open Cap table

Shareholders

StakeFiling
김건수Large holding report (5%)
김찬혁Large holding report (5%)

Open Shareholders

Log in to ask 6ix AI your own questions about Curocell, Inc.